000128883 001__ 128883
000128883 005__ 20240228143355.0
000128883 0247_ $$2doi$$a10.1177/1533034615577515
000128883 0247_ $$2pmid$$apmid:25824268
000128883 0247_ $$2ISSN$$a1533-0338
000128883 0247_ $$2ISSN$$a1533-0346
000128883 037__ $$aDKFZ-2017-04896
000128883 041__ $$aeng
000128883 082__ $$a610
000128883 1001_ $$aKessel, Kerstin A$$b0
000128883 245__ $$aChanges in Gross Tumor Volume and Organ Motion Analysis During Neoadjuvant Radiochemotherapy in Patients With Locally Advanced Pancreatic Cancer Using an In-House Analysis System.
000128883 260__ $$a[Thousand Oaks, CA]$$bSage$$c2016
000128883 3367_ $$2DRIVER$$aarticle
000128883 3367_ $$2DataCite$$aOutput Types/Journal article
000128883 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524748161_17044
000128883 3367_ $$2BibTeX$$aARTICLE
000128883 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128883 3367_ $$00$$2EndNote$$aJournal Article
000128883 520__ $$aDuring radiation treatment, movement of the target and organs at risks as well as tumor response can significantly influence dose distribution. This is highly relevant in patients with pancreatic cancer, where organs at risk lie in close proximity to the target.Data sets of 10 patients with locally advanced pancreatic cancer were evaluated. Gross tumor volume deformation was analyzed. Dose changes to organs at risk were determined with focus on kidneys both without adaptive radiotherapy compensation and with replanning based on weekly acquired computed tomography scans.During irradiation, gross tumor volume changes between 0% and 26% and moves within a radius of 5 to 16 mm. Required maximal dose to organs at risk for kidneys can be met with the current practice of matching computed tomography scans during treatment and adjusting patient position accordingly. Comparison of the mean doses and V15, V20 volumes demonstrated that weekly replanning could bring a significant dose sparing of the left kidney.Manual matching with focus on bony structures can lead to overall acceptable positioning of patients during treatment. Thus, tolerance doses of organs at risk, such as the kidneys, can be met. With adequate margins, normal tissue constraints to organs at risk can be kept as well. Adaptive radiotherapy approaches (in this case with weekly rescanning) reduced dose to organs at risk, which may be especially important for hypofractionated approaches.
000128883 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000128883 588__ $$aDataset connected to CrossRef, PubMed,
000128883 7001_ $$0P:(DE-HGF)0$$aJäger, Andreas$$b1
000128883 7001_ $$aHabermehl, Daniel$$b2
000128883 7001_ $$0P:(DE-HGF)0$$aRüppell, Jan$$b3
000128883 7001_ $$0P:(DE-He78)4e7bb332499544552cf19660bec6f04f$$aBendl, Rolf$$b4$$udkfz
000128883 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b5$$udkfz
000128883 7001_ $$aCombs, Stephanie E$$b6
000128883 773__ $$0PERI:(DE-600)2220436-2$$a10.1177/1533034615577515$$gVol. 15, no. 2, p. 348 - 354$$n2$$p348 - 354$$tTechnology in cancer research & treatment$$v15$$x1533-0338$$y2016
000128883 909CO $$ooai:inrepo02.dkfz.de:128883$$pVDB
000128883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000128883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000128883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4e7bb332499544552cf19660bec6f04f$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000128883 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000128883 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000128883 9141_ $$y2016
000128883 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128883 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128883 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bTECHNOL CANCER RES T : 2015
000128883 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128883 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128883 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128883 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128883 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000128883 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000128883 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000128883 9201_ $$0I:(DE-He78)E071-20160331$$kE071$$lSoftwareentwicklung für Integrierte Diagnostik und Therapie(SIDT)$$x0
000128883 9201_ $$0I:(DE-He78)E040-20160331$$kE040$$lMedizinische Physik in der Strahlentherapie$$x1
000128883 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lKKE Strahlentherapie$$x2
000128883 980__ $$ajournal
000128883 980__ $$aVDB
000128883 980__ $$aI:(DE-He78)E071-20160331
000128883 980__ $$aI:(DE-He78)E040-20160331
000128883 980__ $$aI:(DE-He78)E050-20160331
000128883 980__ $$aUNRESTRICTED